fda compounding semaglutide enforcement news november 2025 March 31, 2025: Senator asks how will be accountable for unregulated active pharmaceutical ingredient (API) imports – Partnership for Safe Medicines New project announcement: HHS‑OIG is

By activating GLP-1 receptors, retatrutide slows gastric emptying the rate at which food moves from the stomach into the small intestine

Where 20242026 head-to-head data is absent, particularly for tirzepatide versus semaglutide nausea incidence, the recommendation is flagged [unverified] rather than inferred across trials with different populations and titration schedules

2 billion more consumers: in key developing markets including India, China, and Brazil, semaglutide patents will expire in 2026

Cost considerations and insurance coverage options

Severe Gastrointestinal Disease People with inflammatory bowel disease, Crohns disease, or other serious GI conditions were largely excluded from retatrutide trials